Covid19-Sources

PDF | Background: The present study investigates the influence of COVID-19 on mortality in the sixteen German federal states. To examine this issue, we... | Find, read and cite all the research you need on ResearchGate

Expression of CCR5 and its cognate ligands have been implicated in COVID-19 pathogenesis, consequently therapeutics directed against CCR5 are being investiga...

Symptome wie Husten, Kurzatmigkeit oder Erschöpfung können nach einer Corona-Infektion noch lange bestehen bleiben. Man spricht dann von Post oder Long Covid. Die Behandlung ist oft komplex.

Individuals infected with the SARS-CoV-2 Delta variant, lineage B.1.617.2, exhibit faster initial infection with a higher viral load than prior variants, and pseudotyped particles bearing the SARS-CoV-2 Delta variant spike protein induce a faster initial infection rate of target cells compared to those bearing other SARS-CoV-2 variant spikes. Here, we show that pseudotyped particles bearing the Delta variant spike form unique aggregates, as evidenced by negative stain and cryogenic electron microscopy (EM), flow cytometry, and nanoparticle tracking analysis. Viral particles pseudotyped with other SARS-CoV-2 spike variants do not show aggregation by any of these criteria. The contribution to infection kinetics of the Delta spike’s unique property to aggregate is discussed with respect to recent evidence for collective infection by other viruses. Irrespective of this intriguing possibility, spike-dependent aggregation is a new functional parameter of spike-expressing viral particles to evaluate in future spike protein variants. ### Competing Interest Statement The authors have declared no competing interest.

Patientinnen oder Patienten, die sich kurz vor oder nach ihrer Operation mit SARS-CoV-2 infizierten, haben laut Studienlage ein erhöhtes Komplikations- und Sterbe- risiko. Das Risiko ist bis zu 7 Wochen nach SARS-CoV-2-Infektion erhöht, auch dann, wenn die Betroffenen kei- ne Symptome aufwiesen, das heißt nur einen positiven Polymeraseket- tenreaktion-(PCR-)Test hatten (1).

To date, no systematic review or meta-analysis has comprehensively estimated the risk of mortality by surgery type on an international scale. We aim to delineate the risk of mortality in patients with COVID-19 who undergo surgery.

Even though more than two years have passed since the global pandemic started, COVID-19 continues to impact children all over the world. The most common course of SARS-CoV-2 infection in children is short term with no or mild symptoms. However, there are two long-term consequences: long COVID and multisystem inflammatory syndrome (MIS-C). A post-COVID19 programme for children has been created in Latvia; however, we know that the availability of this service is limited. We developed an online survey so that we could screen for those paediatric patients with long COVID who needed to see a specialist as soon as possible. The cross-sectional study from 1 November 2021 to 27 March 2022 included 220 patients. In our study, the most frequent symptoms in the age group 1.5 years were irritability (50%), mood swings (50%), persistent cough (33.3%) and loss of appetite (33.3%). In the group aged 1.5–5 years, a persistent cough (54.4%), mood swings (43.9%) and irritability (42.1%) were the most common symptoms, while in the group aged 6–10 years, fatigue (56.6%), abdominal pain (55.3%), headache (50%), and mood swings (50%) were seen most often. Meanwhile in the 11–18 age group, impaired physical activity (66.7%), fatigue (62.3%) and drowsiness (62.3%) were the most frequently seen symptoms.

To compare the prevalence of SARS-CoV-2 and other respiratory viruses in saliva and bioaerosols between two winters and model the probability of virus detection in classroom air for different viruses. Methods We analyze saliva, air, and air cleaner filter samples from studies conducted in two Swiss secondary schools (age 14-17 years) over seven weeks during the winters of 2021/22 and 2022/23. Two bioaerosol sampling devices and HEPA filters from air cleaners were used to collect airborne virus particles in five classrooms. Daily bioaerosol samples were pooled for each sampling device before PCR analysis of a panel of 19 respiratory viruses and viral subtypes. The probability of detection of airborne viruses was modelled using an adjusted Bayesian logistic regression model. Results Three classes (58 students) participated in 2021/22, and two classes (38 students) in 2022/23. During winter 2021/22, SARS-CoV-2 dominated in saliva (19 of 21 positive samples) and bioaerosols (9 of 10). One year later, there were 50 positive saliva samples, mostly influenza B, rhinovirus, and adenovirus, and two positive bioaerosol samples, one rhinovirus and one adenovirus. The weekly probability of airborne detection was 34% (95%-credible interval [CrI] 22%−47%) for SARS-CoV-2 and 10% (95%-CrI 5%-16%) for other respiratory viruses.

A literature review found pneumococcal conjugate vaccines were associated with some protection against flu and other viral respiratory tract infections.

Global adult mortality rates markedly increased during the COVID-19 pandemic in 2020 and 2021, reversing past decreasing trends, while child mortality rates continued to decline, albeit more slowly than in earlier years. Although COVID-19 had a substantial impact on many demographic indicators during the first 2 years of the pandemic, overall global health progress over the 72 years evaluated has been profound, with considerable improvements in mortality and life expectancy. Additionally, we observed a deceleration of global population growth since 2017, despite steady or increasing growth in lower-income countries, combined with a continued global shift of population age structures towards older ages.

The COVID-19 pandemic caused the most severe drops in life expectancy seen in 50+ years.

As our kids return to school this year, it’s worth asking: What was the real impact of school closures during the height of the pandemic? Mehdi Hasan takes a...

During the first wave of the COVID-19 pandemic, Sweden registered a high level of excess deaths. Non-pharmaceutical interventions adopted by Sweden have been milder compared to those implemented in Denmark. Moreover, Sweden might have started the pandemic ...

BackgroundThe spread of SARS-CoV-2 cannot be well monitored and understood in areas without capacity for effective disease surveillance. Countries with a young population will have disproportionately large numbers of asymptomatic or pauci-symptomatic infections, further hindering detection of infection. Sero-surveillance on a country-wide scale by trained medical professionals may be limited in a resource-limited setting such as Mali. Novel ways of broadly sampling the human population in a non-invasive method would allow for large-scale surveillance at a reduced cost.ApproachHere we evaluate the collection of naturally blood-fed mosquitoes to test for human anti-SARS-CoV-2 antibodies in the laboratory and at five field locations in Mali.ResultsImmunoglobulin-G antibodies to multiple SARS-CoV-2 antigens were readily detected in mosquito bloodmeals by bead-based immunoassay through at least 10 h after feeding [mean sensitivity of 0.92 (95% CI 0.78–1) and mean specificity of 0.98 (95% CI 0.88–1)], indicating that most blood-fed mosquitoes collected indoors during early morning hours (and likely to have fed the previous night) are viable samples for analysis. We found that reactivity to four SARS-CoV-2 antigens rose during the pandemic from pre-pandemic levels. The crude seropositivity of blood sampled via mosquitoes was 6.3% in October and November 2020 across all sites, and increased to 25.1% overall by February 2021, with the most urban site reaching 46.7%, consistent with...

Cognitive decline is a common adverse effect of the Coronavirus Disease of 2019 (COVID-19), particularly in the post-acute disease phase. The mechanisms of cognitive impairment after COVID-19 (COGVID) remain unclear, but neuroimaging studies provide evidence of brain changes, many that are associated with aging. Therefore, we calculated Brain Age Gap (BAG), which is the difference between brain age and chronological age, in a cohort of 25 mild to moderate COVID-19 survivors (did not experience breathlessness, pneumonia, or respiratory/organ failure) and 24 non-infected controls (mean age = 30 +/- 8) using magnetic resonance imaging (MRI). BAG was significantly higher in the COVID-19 group (F = 4.22, p = 0.046) by 2.65 years. Additionally, 80% of the COVID-19 group demonstrated an accelerated BAG compared to 13% in the control group (X2 = 20.0, p 0.001). Accelerated BAG was significantly correlated with lower cognitive function (p 0.041). Females in the COVID-19 group demonstrated a 99% decreased risk of accelerated BAG compared to males (OR = 0.015, 95% CI: 0.001 to 0.300). There was also a small (1.4%) but significant decrease in risk for accelerated BAG associated with longer time since COVID-19 diagnosis (OR = 0.986, 95% CI: 0.977 to 0.995). Our findings provide a novel biomarker of COGVID and point to accelerated brain aging as a potential mechanism of this adverse effect. Our results also offer further insight regarding gender-related disparities in cognitive morbidity associated with COVID-19. ### Competing Interest Statement The authors have declared no competing interest. ### Funding Statement This study did not receive any funding ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: This study was approved by the University of Texas at Austin Institutional Review Board (protocol# 00001337). I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes The datasets generated and analyzed during the current study are not publicly available due the fact that they constitute an excerpt of research in progress but will be available on the EBRAINS platform (https://www.ebrains.eu) under the corresponding author name at study completion. Interested parties may contact the corresponding author for further information.

Correspondence from The New England Journal of Medicine — Prospective Memory Assessment before and after Covid-19

Original Article from The New England Journal of Medicine — Cognition and Memory after Covid-19 in a Large Community Sample

DMZ – POLITIK / WISSEN / GESUNDHEIT ¦ AA ¦ Der Beitrag im "Pandemic Accountability Index" (Pandemie-Verantwortlichkeitsindex) vom letzten November, in dem über hundert Studien und Artikel zu den Auswirkungen des SARS-CoV-2-Virus auf den Körper berichtet wurde, ist mittlerweile über sechs Monate alt. Seitdem wurden weitere Forschungsergebnisse veröffentlicht. Es ist daher an der Zeit, unser Verständnis dafür zu aktualisieren, warum es so wichtig ist, Infektionen mit diesem gefährlichen und behindernden Virus zu verhindern. Laut der Weltgesundheitsorganisation (WHO) leiden allein in Europa über 36 Millionen Menschen an Langzeitfolgen von COVID, einem Oberbegriff für zahlreiche medizinische Komplikationen. Diejenigen, die behauptet haben, dass SARS-CoV-2 relativ harmlos oder "mild" sei und COVID-19 "nur eine Erkältung/Grippe" sei, müssen sich mit der ständig wachsenden Anzahl wissenschaftlicher Forschungsergebnisse auseinandersetzen, die seitdem veröffentlicht wurden. Kinder und COVID: COVID-19 ist eine der häufigsten Todesursachen bei Kindern und Jugendlichen in den USA (University of Oxford). Anstieg von Diabetes bei Kindern und Jugendlichen (Jama Network). Auch milde Infektionen können zu langfristigen Folgen führen, einschließlich Long-COVID (University of Minnesota). Mehr als 70% der Haushaltsübertragungen von COVID in den USA gehen von Kindern aus (CIDRAP). Kinder können nach einer asymptomatischen oder milden COVID-19-Erkrankung langfristige Herzmuskeldeformationen entwickeln (MDPI Open Access Journals). Langzeitfolgen bei Jugendlichen und jungen Erwachsenen nach mildem COVID-19 (Frontiers in Immunology). Einige Kinder zeigen nach einer COVID-19-Infektion Symptome wie Fieber, Erbrechen und Augenschmerzen (NHK). COVID-19 kann bei Kindern autoimmune Reaktionen auslösen (HCPLive). Erhöhte Raten von Asthma, Myokarditis, Diabetes und anderen Erkrankungen bei Kindern mit bestätigtem COVID-19 (Medical Journal of Australia). Über 30% der Kinder zeigen auch nach 2 Monaten noch Symptome, und 2,3% haben nach 6 Monaten immer noch anhaltende Symptome (Frontiers in Pediatrics). Das Immunsystem von Kindern entwickelt keine "adaptiven" Erinnerungen, die vor einer erneuten SARS-CoV-2-Infektion schützen (Garvan Institute of Medical Research). Die Prävalenz von Langzeitfolgen bei COVID-19 liegt bei 23,36% (ScienceDirect). Die Omikron-Variante verursacht siebenmal mehr Todesfälle bei hospitalisierten Kindern als die Influenza (South China Morning Post). In Ohio haben zwischen 30.000 und 70.000 Kinder Long COVID (US News). COVID-19 kann zu Herzerkrankungen bei Kindern führen (MDPI Open Access Journals). Entzündliche Erkrankungen bei Kindern nach COVID-19 (ScienceDirect). Neurologische Komplikationen nach COVID-19 bei Kindern (American Academy of Pediatrics). Augenmanifestationen von COVID-19 bei Kindern (SageJournals). Beeinträchtigungen der Gesundheit bei Kindern und Jugendlichen nach einer COVID-19-Erkrankung (American Academy of Pediatrics). Nahezu alle mit COVID-19 infizierten Kinder zeigen Anzeichen von Schädigung der Blutgefäße (Blood Advances). Eine Studie zeigt, dass vorherige COVID-19-Infektionen mit einem signifikant erhöhten Risiko für RSV-Infektionen bei Kindern in Verbindung gebracht werden (medRxiv). Zwischen 12 und 16% der Kinder und Jugendlichen, die mit Omikron infiziert waren, erfüllen die Definition von Long COVID (Journal of Pediatrics). Diabetes-Typ-1-Inzidenz und -Risiko bei Kindern mit einer COVID-19-Diagnose (Jama Network). Prävalenz von Long COVID bei Kindern und Jugendlichen beträgt 25,24%, am häufigsten mit Stimmungssymptomen (Nature). Ungewöhnlicher Anstieg von Hirnabszessen bei amerikanischen Kindern (CDC). Veränderte Verformung der roten Blutkörperchen bei Kindern und Jugendlichen nach SARS-CoV-2-Infektion (Nature). Kinder haben ein ähnliches Risiko für Langzeitfolgen von Long COVID bei einer erneuten Infektion wie bei der Erstinfektion (Journal of Pediatrics). SARS-CoV-2 kann sich über Wochen bis Monate systemisch ausbreiten und persistieren, unabhängig von der Schwere der Erkrankung (Lancet). Originallinks: COVID-19 is a leading cause of death in children and young people in the US (University of Oxford) Surge in child and teen diabetes (Jama Network) “Two US studies describe pediatric COVID...7.0% of hospitalized children developed neurologic complications such as seizures...even mild infections can lead to long COVID.” (University of Minnesota) More than 70% of US household COVID spread started with a child (CIDRAP) "Persistence of LV myocardial deformation abnormalities in previously healthy children with an asymptomatic or mildly symptomatic COVID-19 course after an average follow-up of 148 ± 68 days.” (MDPI Open Access Journals) “Inflammatory markers and pulmonary function in adolescents and young adults 6 months after mild COVID-19” (Frontiers in Immunology) “Fever, vomiting, and eye pain are a few of the symptoms afflicting a small number of children after they have been infected with COVID-19.” (NHK) COVID-19 May Trigger Autoimmune Responses in Children (HCPLive) “…increased rates of asthma, myocarditis and cardiomyopathy, cardiac dysrhythmias, diabetes, renal failure, venous thromboembolism, and coagulation disorders in children with laboratory‐confirmed COVID‐19 compared with children without COVID‐19.” (Medical Journal of Australia) “32.6% of the children had persistent symptoms at 2 months, 9.3% at 4 months, and 2.3% at 6 months” (Frontiers in Pediatrics) Children’s immune systems do not develop ‘adaptive’ memory to protect against second time SARS-CoV-2 infection (Garvan Institute of Medical Research) Based on 40 studies with 12,424 individuals, the pooled prevalence of any long COVID was 23.36 % (ScienceDirect) “Omicron strain causes 7 times more deaths among hospitalised children than influenza” (South China Morning Post) “In Ohio, between 30,000 and 70,000 children have long COVID.” (US News) COVID-19 Heart Lesions in Children: Clinical, Diagnostic and Immunological Changes (MDPI Open Access Journals) Multisystem inflammatory syndrome in children: A dysregulated autoimmune disorder following COVID-19 (ScienceDirect) COVID-19 and Acute Neurologic Complications in Children (American Academy of Pediatrics) Ocular manifestations of COVID-19 in pediatric patients (SageJournals) Health Impairments in Children and Adolescents After Hospitalization for Acute COVID-19 or MIS-C (American Academy of Pediatrics) "Virtually all children infected with COVID-19 show signs of blood vessel damage" (Blood Advances) "Findings from our study support that prior COVID-19 infection was associated with a significantly increased risk for RSV infection and was a driving force for the 2022 surge of severe pediatric RSV cases in the US." (medRxiv) “12-16% children and youth infected with Omicron met the research definition of #LongCovid at 3 and 6 months after infection, with no evidence of difference between cases of first-positive and reinfection” (Journal of Pediatrics) Type 1 Diabetes Incidence and Risk in Children With a Diagnosis of COVID-19 (Jama Network) Long-COVID in children and adolescents: prevalence of long-COVID was 25.24%, most prevalent clinical: mood symptoms (16.50%) - (Nature) Abnormal Surge of Brain Abscesses in American Children, CDC Says (ScienceAlert) Increased red blood cell deformation in children and adolescents after SARS-CoV-2 infection (Nature) Children are at as much risk of Long COVID disability from reinfection as they are from primary infection (Journal of Pediatrics) “in children, independent from disease severity, SARS-CoV-2 can spread systemically and persist for weeks to months.” (Lancet) NEUROLOGISCHE BEEINTRÄCHTIGUNGEN: Geruchs- und Geschmacksstörungen nach COVID-19 (BMJ). Neuropsychologische Defizite bei Patienten mit anhaltenden COVID-19-Symptomen (Nature). Neuroinflammation nach COVID-19 mit anhaltenden depressiven und kognitiven Symptomen (JAMA Psychiatry). SARS-CoV-2 fördert die Beseitigung synaptischer Verbindungen durch Mikrogliazellen im menschlichen Gehirn (Nature). Langfristige Auswirkungen von COVID-19 auf kognitive Funktionen bis zu 6 Monate nach der Entlassung: Rolle von Depressionen und Auswirkungen auf die Lebensqualität (Springer Link). SARS-CoV-2 ist mit Veränderungen der Gehirnstruktur verbunden (Nature). Jeder vierte Patient zeigt kognitive Defizite nach einem milden COVID-19-Verlauf (NIH). Neurokognitive und psychiatrische Symptome nach COVID-19-Infektion: Nachweise aus Labor- und Bevölkerungsstudien (ScienceDirect). COVID-19 und kognitive Beeinträchtigungen: Neuroinvasive und Blut-Hirn-Schrankenstörungen (Journal of Neuroinflammation). COVID-19 kann dazu führen, dass Gehirnzellen abnormal fusionieren und Beeinträchtigungen der Gehirnfunktion verursachen, bei 10% der untersuchten Fälle kommt die neuronale Aktivität vollständig zum Stillstand (ScienceAdvances). COVID-19 kann auch durch Hyperaktivierung der Immunantwort, Zelltod oder Entzündungen verschiedene Hirnregionen beeinträchtigen und zu Gedächtnisstörungen führen (CIDRAP). Rasche Verschlechterung der Demenz nach COVID-19 (NIH). Originallinks: Smell and taste dysfunction after covid-19 (BMJ) Neuropsychological deficits in patients with persistent COVID-19 symptoms (Nature) Neuroinflammation After COVID-19 With Persistent Depressive and Cognitive Symptoms (JAMA Psychiatry) SARS-CoV-2 promotes microglial synapse elimination in human brain organoids (Nature) Long-term consequences of COVID-19 on cognitive functioning up to 6 months after discharge: role of depression and impact on quality of life (Springer Link) SARS-CoV-2 is associated with changes in brain structure (Nature) 1 in 4 Showing Cognitive Deficits After Mild Case (NIH) Neurocognitive and psychiatric symptoms following infection with COVID-19: Evidence from laboratory and population studies (ScienceDirect) COVID-19 and cognitive impairment: neuroinvasive and blood‒brain barrier dysfunction (Journal of Neuroinflammation) Covid causes b

In 2002–03, a Severe Acute Respiratory Syndrome (SARS) coronavirus caused a pandemic. It was described as a novel virus, meaning that it seemed to be unrelated

The diseases are nowhere near the same.

Sterilising immunity means that the immune system is able to completely prevent a virus from replicating in your body. Not all vaccines provide this.

AbstractAims. This study aims to evaluate the short- and long-term associations between COVID-19 and development of cardiovascular disease (CVD) outcomes and mo

Nach einem Antikörper-Cocktail waren Long-Covid-Patienten symptomfrei – die experimentelle Therapie macht Hoffnung für zukünftige Behandlungen. Drei spannende Case Reports.

Oxford – Persistierende Infektionen mit SARS-CoV-2, die ursprünglich nur bei immungeschwächten Personen vermutet wurden, treten auch in der Allgemeinbevölkerung...

This study investigated the effectiveness of natural infection in preventing reinfection with the JN.1 variant during a large JN.1 wave in Qatar, using a test-negative case-control study design. The overall effectiveness of previous infection in preventing reinfection with JN.1 was estimated at only 1.8% (95% CI: -9.3-12.6%). This effectiveness demonstrated a rapid decline over time since the previous infection, decreasing from 82.4% (95% CI: 40.9-94.7%) within 3 to less than 6 months after the previous infection to 50.9% (95% CI: -11.8-78.7%) in the subsequent 3 months, and further dropping to 18.3% (95% CI: -34.6-56.3%) in the subsequent 3 months. Ultimately, it reached a negligible level after one year. The findings show that the protection of natural infection against reinfection with JN.1 is strong only among those who were infected within the last 6 months, with variants such as XBB*. However, this protection wanes rapidly and is entirely lost one year after the previous infection. The findings support considerable immune evasion by JN.1. ### Competing Interest Statement The authors have declared no competing interest. ### Funding Statement The authors are grateful for support from the Biomedical Research Program and the Biostatistics, Epidemiology, and Biomathematics Research Core at Weill Cornell Medicine in Qatar; the Qatar Ministry of Public Health; Hamad Medical Corporation; and Sidra Medicine. The authors are also grateful for the Qatar Genome Programme and Qatar University Biomedical Research Center for institutional support for the reagents needed for the viral genome sequencing. ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: The institutional review boards at Hamad Medical Corporation and Weill Cornell Medicine in Qatar approved this retrospective study with a waiver of informed consent. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes The dataset of this study is a property of the Qatar Ministry of Public Health that was provided to the researchers through a restricted access agreement that prevents sharing the dataset with a third party or publicly. Future access to this dataset can be considered through a direct application for data access to Her Excellency the Minister of Public Health (https://www.moph.gov.qa/english/Pages/default.aspx). Aggregate data are available within the manuscript and its Supplementary information.

Microbial infections activate the innate and adaptive immune systems.1 Pathogen-associated molecular patterns produced by microbes, such as double-stranded RNA, are detected by PRRs (pattern-recognit

Long Covid provides an opportunity to understand how acute infections cause chronic disease